{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:31:31Z","timestamp":1782408691503,"version":"3.54.5"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:p>High-dose methotrexate has been a treatment for osteosarcoma; however, its nephrotoxic effects are considerable. Carboxypeptidase-G2 (glucarpidase) was approved by the US Food and Drug Administration in 2012 for treatment of toxic methotrexate levels. We report our experience using glucarpidase under compassionate use before Food and Drug Administration approval in 2 patients who had delayed methotrexate clearance and prolonged kidney injury despite glucarpidase administration. Our results show that patients with methotrexate toxicity may require repeated doses of glucarpidase in addition to supportive measures, such as dialysis.<\/jats:p>","DOI":"10.1097\/mph.0000000000001058","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T19:58:55Z","timestamp":1513108735000},"page":"152-155","source":"Crossref","is-referenced-by-count":7,"title":["Delayed Methotrexate Clearance Despite Carboxypeptidase-G2 (Glucarpidase) Administration in 2 Patients With Toxic Methotrexate Levels"],"prefix":"10.1097","volume":"40","author":[{"given":"Kirk D.","family":"Wyatt","sequence":"first","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Cooper","sequence":"additional","affiliation":[{"name":"Billings Clinic, Billings, MT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Scott","sequence":"additional","affiliation":[{"name":"Bronson Health, Kalamazoo, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Broomall","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Altaf","sequence":"additional","affiliation":[{"name":"Aga Khan University Hospital, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Hogan","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilmarie","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakila","family":"Khan","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome","volume":"28","author":"Widemann","year":"2010","journal-title":"J Clin Oncol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1373\/clinchem.2010.144824","article-title":"Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity","volume":"56","author":"Al-Turkmani","year":"2010","journal-title":"Clin Chem"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2146\/ajhp130483","article-title":"Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function","volume":"71","author":"Fermiano","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1634\/theoncologist.12-11-1299","article-title":"Glucarpidase (carboxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy","volume":"12","author":"Schwartz","year":"2007","journal-title":"The Oncologist"},{"key":"R9-20230918","first-page":"732","article-title":"Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity","volume":"38","author":"Rattu","year":"2013","journal-title":"Pharm Therap"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/pbc.25395","article-title":"Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients","volume":"62","author":"Scott","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1749-6632.1971.tb46920.x","article-title":"Metabolism of anticancer agents in man","volume":"179","author":"Adamson","year":"1971","journal-title":"Ann N Y Acad Sci"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM197709222971203","article-title":"Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity","volume":"297","author":"Stoller","year":"1977","journal-title":"N Engl J Med"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1983.1.3.208","article-title":"Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine","volume":"1","author":"Abelson","year":"1983","journal-title":"J Clin Oncol"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/ki.1988.60","article-title":"Extracorporeal techniques in the treatment of exogenous intoxications","volume":"33","author":"Garella","year":"1988","journal-title":"Kidney Int"},{"issue":"5B","key":"R17-20230918","first-page":"3051","article-title":"Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism","volume":"28","author":"Muller","year":"2008","journal-title":"Anticancer Res"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2217\/pgs.14.97","article-title":"Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies","volume":"15","author":"Suthandiram","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12185-013-1464-z","article-title":"Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy","volume":"98","author":"Yanagimachi","year":"2013","journal-title":"Int J Hematol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/1078155215594417","article-title":"Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity","volume":"22","author":"Wiczer","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1002\/cncr.27378","article-title":"Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients","volume":"118","author":"Christensen","year":"2012","journal-title":"Cancer"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201803000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:16:31Z","timestamp":1695010591000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201803000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001058","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}